title: TRK Inhibitor Shows Early Promise.
abstract: Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy.
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D014178:Translocation, Genetic / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D015514:Oncogene Proteins, Fusion; D011720:Pyrazoles; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases; C000609083:larotrectinib